<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aline Hébrant</style></author><author><style face="normal" font="default" size="100%">K Punie</style></author><author><style face="normal" font="default" size="100%">FP Duhoux</style></author><author><style face="normal" font="default" size="100%">C Colpaert</style></author><author><style face="normal" font="default" size="100%">G Floris</style></author><author><style face="normal" font="default" size="100%">K Lambein</style></author><author><style face="normal" font="default" size="100%">P Neven</style></author><author><style face="normal" font="default" size="100%">M Berlière</style></author><author><style face="normal" font="default" size="100%">R Salgado</style></author><author><style face="normal" font="default" size="100%">M Chintinne</style></author><author><style face="normal" font="default" size="100%">K Dahan</style></author><author><style face="normal" font="default" size="100%">S Dedeurwaerdere</style></author><author><style face="normal" font="default" size="100%">J De Grève</style></author><author><style face="normal" font="default" size="100%">A de Leener</style></author><author><style face="normal" font="default" size="100%">H Denys</style></author><author><style face="normal" font="default" size="100%">R de Putter</style></author><author><style face="normal" font="default" size="100%">L Desmyter</style></author><author><style face="normal" font="default" size="100%">M Baldewijns</style></author><author><style face="normal" font="default" size="100%">D Feret</style></author><author><style face="normal" font="default" size="100%">C Fontaine</style></author><author><style face="normal" font="default" size="100%">C Galant</style></author><author><style face="normal" font="default" size="100%">P Hilbert</style></author><author><style face="normal" font="default" size="100%">J Janssens</style></author><author><style face="normal" font="default" size="100%">D Larsimont</style></author><author><style face="normal" font="default" size="100%">P Lefesvre</style></author><author><style face="normal" font="default" size="100%">T Sticca</style></author><author><style face="normal" font="default" size="100%">MD Tkint de Roodenbeke</style></author><author><style face="normal" font="default" size="100%">I Vanden Bempt</style></author><author><style face="normal" font="default" size="100%">C Van den Broeck</style></author><author><style face="normal" font="default" size="100%">I Vandernoot</style></author><author><style face="normal" font="default" size="100%">C Sotiriou</style></author><author><style face="normal" font="default" size="100%">J Van Dorpe</style></author><author><style face="normal" font="default" size="100%">H Antoine-Poirel</style></author><author><style face="normal" font="default" size="100%">Els Van Valckenborgh</style></author><author><style face="normal" font="default" size="100%">Gordana Raicevic</style></author><author><style face="normal" font="default" size="100%">Marc Van den Bulcke</style></author><author><style face="normal" font="default" size="100%">P Aftimos</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Molecular test algorithms for breast tumours</style></title><secondary-title><style face="normal" font="default" size="100%">Belgian Journal of Medical Oncology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">45</style></number><volume><style face="normal" font="default" size="100%">13</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;In order to advise the Federal Government on all matters related to personalised medicine in oncology, including the reimbursement of molecular tests, the Commission of Personalized Medicine (ComPerMed) has applied, for the breast tumours, the same methodology as previously applied for the digestive tumours. Meaning, the different molecular tests, represented in the shape of algorithms, are annotated with test levels — which aim to reflect their relevance based on current available data and to define the reimbursement — and are documented with recent literature, guidelines and a brief technical description.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><section><style face="normal" font="default" size="100%">40</style></section></record></records></xml>